Erin E Crotty1,2, Stephanie M C Smith3,4, Ken Brasel5,6, Fiona Pakiam5, Emily J Girard5, Yamicia D Connor3,7, Frederique Zindy3, Andrew J Mhyre5, Martine F Roussel3, James M Olson8,5. 1. Division of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA. Erin.Crotty@fredhutch.org. 2. Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA. Erin.Crotty@fredhutch.org. 3. Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, TN, USA. 4. Medtronic, Department of Clinical Strategy, 1775, Pyramid Place TN03, Memphis, TN, 38132, USA. 5. Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA. 6. Century Therapeutics, 3675 Market St., Philadelphia, PA, 19104, USA. 7. Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA, 02115, USA. 8. Division of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Abstract
PURPOSE: Tumor infiltration by immunosuppressive myeloid cells or tumor-associated macrophages (TAMs) contributes to tumor progression and metastasis. In contrast to their adult counterparts, higher TAM signatures do not correlate with aggressive tumor behavior in pediatric brain tumors. While prominent TAM infiltrates exist before and after radiation, the degree to which irradiated macrophages and microglia support progression or leptomeningeal metastasis remains unclear. Patients with medulloblastoma often present with distant metastases and tumor recurrence is largely incurable, making them prime candidates for the study of novel approaches to prevent neuroaxis dissemination and recurrence. METHODS: Macrophage depletion was achieved using CSF-1 receptor inhibitors (CSF-1Ri), BLZ945 and AFS98, with or without whole brain radiation in a variety of medulloblastoma models, including patient-derived xenografts bearing Group 3 medulloblastoma and a transgenic Sonic Hedgehog (Ptch1+/-, Trp53-/-) medulloblastoma model. RESULTS: Effective reduction of microglia, TAM, and spinal cord macrophage with CSF-1Ri resulted in negligible effects on the rate of local and spinal recurrences or survival following radiation. Results were comparable between medulloblastoma subgroups. While notably few tumor-infiltrating lymphocytes (TILs) were detected, average numbers of CD3+ TILs and FoxP3+ Tregs did not differ between groups following treatment and tumor aggressiveness by Ki67 proliferation index was unaltered. CONCLUSION: In the absence of other microenvironmental influences, medulloblastoma-educated macrophages do not operate as tumor-supportive cells or promote leptomeningeal recurrence in these models. Our data add to a growing body of literature describing a distinct immunophenotype amid the medulloblastoma microenvironment and highlight the importance of appropriate pediatric modeling prior to clinical translation.
PURPOSE: Tumor infiltration by immunosuppressive myeloid cells or tumor-associated macrophages (TAMs) contributes to tumor progression and metastasis. In contrast to their adult counterparts, higher TAM signatures do not correlate with aggressive tumor behavior in pediatric brain tumors. While prominent TAM infiltrates exist before and after radiation, the degree to which irradiated macrophages and microglia support progression or leptomeningeal metastasis remains unclear. Patients with medulloblastoma often present with distant metastases and tumor recurrence is largely incurable, making them prime candidates for the study of novel approaches to prevent neuroaxis dissemination and recurrence. METHODS: Macrophage depletion was achieved using CSF-1 receptor inhibitors (CSF-1Ri), BLZ945 and AFS98, with or without whole brain radiation in a variety of medulloblastoma models, including patient-derived xenografts bearing Group 3 medulloblastoma and a transgenic Sonic Hedgehog (Ptch1+/-, Trp53-/-) medulloblastoma model. RESULTS: Effective reduction of microglia, TAM, and spinal cord macrophage with CSF-1Ri resulted in negligible effects on the rate of local and spinal recurrences or survival following radiation. Results were comparable between medulloblastoma subgroups. While notably few tumor-infiltrating lymphocytes (TILs) were detected, average numbers of CD3+ TILs and FoxP3+ Tregs did not differ between groups following treatment and tumor aggressiveness by Ki67 proliferation index was unaltered. CONCLUSION: In the absence of other microenvironmental influences, medulloblastoma-educated macrophages do not operate as tumor-supportive cells or promote leptomeningeal recurrence in these models. Our data add to a growing body of literature describing a distinct immunophenotype amid the medulloblastoma microenvironment and highlight the importance of appropriate pediatric modeling prior to clinical translation.
Authors: Michael J Campbell; Nathan Y Tonlaar; Elisabeth R Garwood; Dezheng Huo; Dan H Moore; Andrey I Khramtsov; Afred Au; Frederick Baehner; Yinghua Chen; David O Malaka; Amy Lin; Oyinlolu O Adeyanju; Shihong Li; Can Gong; Michael McGrath; Olufunmilayo I Olopade; Laura J Esserman Journal: Breast Cancer Res Treat Date: 2010-09-15 Impact factor: 4.872
Authors: Jason H Stafford; Takahisa Hirai; Lei Deng; Sophia B Chernikova; Kimiko Urata; Brian L West; J Martin Brown Journal: Neuro Oncol Date: 2015-11-03 Impact factor: 12.300
Authors: Christian Steidl; Arjan Diepstra; Tang Lee; Fong Chun Chan; Pedro Farinha; King Tan; Adele Telenius; Lorena Barclay; Sohrab P Shah; Joseph M Connors; Anke van den Berg; Randy D Gascoyne Journal: Blood Date: 2012-09-05 Impact factor: 22.113
Authors: Victoria Sofia Berenice Wies Mancini; Anabella Ayelen Di Pietro; Laura Andrea Pasquini Journal: Neural Regen Res Date: 2023-02 Impact factor: 6.058